Table 4.
Effective doses for whole body in mSv and absorbed doses for normal organs in Gy after the administration of varying therapeutic activities of [64Cu]CuCl2 and 177Lu-PSMA
| Estimations for [64Cu]CuCl2 (This work) | ||||||
| Activity (GBq) | Whole body | Liver | Kidney | Pancreas | Lower large intestine | Upper large intestine |
| 4.0 | 226±24 | 1.46±0.35 | 0.32±0.11 | 0.38±0.07 | 0.64±0.19 | 0.55±0.16 |
| 8.0 | 452±48 | 2.93±0.70 | 0.64±0.21 | 0.76±0.13 | 1.27±0.38 | 1.10±0.31 |
| 12.0 | 678±72 | 4.39±1.04 | 0.96±0.32 | 1.14±0.20 | 1.91±0.56 | 1.66±0.47 |
| Estimations for 177Lu-PSMA (Okamoto et al. 2017 [19]) | ||||||
| Activity (GBq) | Whole body | Liver | Kidney | Parotic glands | Submandibular glands | Lacrimal glands |
| 4.0 | 240±12 | 0.48±0.24 | 2.88±0.84 | 2.2±0.6 | 2.6±1.60 | 15.2±6.6 |
| 8.0 | 480±24 | 0.96±0.48 | 5.76±1.68 | 4.4±1.1 | 5.1±3.2 | 30.4±11.2 |
| 12.0 | 720±36 | 1.44±0.72 | 8.64±2.52 | 6.6±1.7 | 7.7±4.8 | 45.6±16.8 |